<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253340</url>
  </required_header>
  <id_info>
    <org_study_id>2017/183/HP</org_study_id>
    <nct_id>NCT04253340</nct_id>
  </id_info>
  <brief_title>Study of a Bone Assessment Technique, Bone Mineral Analyser, Concerning the Prediction of Improvement in Bone Status After an Infusion of Zoledronic Acid in Osteoporotic Women</brief_title>
  <acronym>TEOBASO</acronym>
  <official_title>Study of a Bone Assessment Technique, Bone Mineral Analyser, Concerning the Prediction of Improvement in Bone Status After an Infusion of Zoledronic Acid in Osteoporotic Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Collection of epidemiological data

        -  Biological assessment as part of routine care.

        -  Measurement of the Hurst coefficient at D0

        -  Measurement of bone density and TBS on D0

        -  Zoledronic acid infusion the month following inclusion

        -  phone call at 1 month (observance of zoledronic acid)

        -  Measurement of bone density, calculation of the Hurst coefficient at M12
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hurst coefficient</measure>
    <time_frame>Day 0</time_frame>
    <description>measured by the BMA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hurst coefficient</measure>
    <time_frame>Month 12</time_frame>
    <description>measured by the BMA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone texture parameters</measure>
    <time_frame>Day 0</time_frame>
    <description>bone texture parameters measured by Trabecular Bone Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone texture parameters</measure>
    <time_frame>Month 12</time_frame>
    <description>bone texture parameters measured by Trabecular Bone Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>Day 0</time_frame>
    <description>Bone mineral density measured by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>Month12</time_frame>
    <description>Bone mineral density measured by DXA scan</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Bone mineral analyser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diagnostic Test: Bone mineral analyser
high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Bone mineral analyser</intervention_name>
    <description>high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12</description>
    <arm_group_label>Bone mineral analyser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women &lt; 85 years old

          -  Postmenopausal women (amenorrhea for more than 12 months), a confirmation diagnosis
             should be obtained (amenorrhea for at least 12 months before the inclusion visit).

          -  Post-menopausal osteoporosis with one or more severe fractures (upper end of the
             humerus, femur, or tibia; 3 adjacent ribs; lower end of the femur; thoracic or lumbar
             spine; pelvis), or T score &lt;-3 which justifies setting up a bisphosphonate treatment

          -  Affiliated to social security

        Exclusion Criteria:

          -  Contraindication to zoledronic acid (allergy to the product, creatinine clearance &lt;35
             ml / min, hypocalcemia, open and unhealed lesions of the soft tissues of the mouth)

          -  Hormone replacement therapy taken in the last 12 months

          -  Osteoprotective treatment (bisphosphonates, teriparatide, raloxifene, strontium
             ralenate or denosumab) taken in the last 12 months

          -  Secondary osteoporosis: hyperthyroidism, hyperparathyroidism, long-term corticosteroid
             therapy, hypercorticism, hypogonadism, treatment with anti aromatases / LHRH
             analogues, neoplastic pathology (solid or hemopathy)

          -  History of bilateral wrist or femur fracture

          -  Person deprived of liberty by an administrative or judicial decision or person placed
             under the protection of justice / guardianship or curatorship

          -  Patient participating in another trial / having participated in another trial within 6
             months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

